BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal

A day after getting a nice fat—and sorely needed—paycheck from Bristol Myers Squibb, BridgeBio has added $110 million to its coffers by selling off a priority review voucher.

Before this week, BridgeBio needed rescuing. The company had resorted to layoffs after a baffling phase 3 failure for its lead transthyretin amyloidosis drug candidate acoramidis late last year. Earlier in May, the company put out a plea for deals to out-license six of its other therapies in development.